A First-in-Human Trial of DS3790a for Hematological Malignancies
This clinical trial is testing a new drug called DS3790a, both by itself and in combination with other drugs, for people with hematological (blood) cancers, specifically B-cell Non-Hodgkin Lymphoma. The main goals are to see how safe DS3790a is and if it causes any serious side effects. Researchers will also look at how well DS3790a works to shrink or get rid of the cancer. You might be able to join if you are an adult (18 years or older) with a confirmed hematological malignancy as specified in the study. The study is currently recruiting up to 420 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 420 participants, but the phase is not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for up to 5 years to monitor for side effects and treatment response.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
At a glance
Conditions
NCT07220616
Where you'd take part
This study runs at 8 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Research Site
New York, New Yorkno site contact published
Recruiting
Research Site
Lille, Franceno site contact published
Recruiting
Research Site
Pierre-Bénite, Franceno site contact published
Recruiting
Research Site
Villejuif, Franceno site contact published
Recruiting
Research Site
Bologna, Italyno site contact published
Recruiting
Research Site
Nagoya, Japanno site contact published
Recruiting
Research Site
Tokyo, Japanno site contact published
Recruiting
Research Site
Tokyo, Japanno site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants Reporting Dose-limiting Toxicities, Treatment-emergent Adverse Events, Serious Adverse Events, Adverse Events of Special Interest, and Deaths in Participants With Hematological MalignanciesBaseline up to 5 years
Adverse events (AEs) will be graded using NCI-CTCAE version 5.0.
- Complete Response in Participants With Hematological Malignancies by Blinded Independent Central Review (Cohort A Randomization Optimization Phase, Cohort A Phase 2)Baseline up to 5 years
Complete Response (CR) is defined as participants with CR as measured by BICR assessment.
- Complete Response in Participants With Hematological Malignancies by Investigator Assessment (Cohort B Randomization Optimization Phase)Baseline up to 5 years
Complete Response (CR) is defined as participants with CR as measured by investigator assessment.